Akèy › Maladi Alzheimer › Michigan
Etid klinik pou Maladi Alzheimer nan Michigan
15 etid pou Maladi Alzheimer ap chèche patisipan nan sit nan Michigan.
Vil nan Michigan
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Local Institution - 1620, Troy
Ap rekriteFaz 3
Laj 55 a 90 · Tout sèks · Mizajou Sep 28, 2026 · NCT06937229A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
- Quest Research Institute, Farmington Hills
Ap rekriteFaz 4
Laj 50 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07633470A Study of LY3439539 in Participants With Alzheimer's Disease
- QUEST Research Institute, Farmington Hills
Ap rekriteFaz 1
Laj 50 a 85 · Tout sèks · Mizajou Sep 24, 2026 · NCT07598370A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
- QUEST Research Institute, Farmington Hills
Ap rekriteFaz 2
Laj 55 a 85 · Tout sèks · Mizajou Sep 22, 2026 · NCT07589595A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Neurobehavioral Medicine Group (NBMG), Bloomfield Township
Ap rekriteFaz 3
Laj 55 a 90 · Tout sèks · Mizajou Sep 22, 2026 · NCT06585787Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Quest Research Institute, Farmington Hills
Ap rekriteFaz 3
Laj 50 a 90 · Tout sèks · Mizajou Sep 21, 2026 · NCT07177352A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
- QUEST Research Institute, Farmington Hills
Ap rekriteFaz 3
Laj 60 a 85 · Tout sèks · Mizajou Sep 17, 2026 · NCT06976203A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- NeuroBehavioral Medicine Group, Bloomfield Hills
- Oakland Medical Research, Troy
Ap rekriteFaz 3
Laj 55 a 90 · Tout sèks · Mizajou Sep 16, 2026 · NCT07011732Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders
- Michigan Medicine, Ann Arbor
Ap rekrite
Laj 70 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT05929703Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
- Local Institution - 0088, Sterling Heights
Ap rekriteFaz 2
Laj 55 a 90 · Tout sèks · Mizajou Sep 1, 2026 · NCT06808984Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Henry Ford Health System, Detroit
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Aug 4, 2026 · NCT06563895Michigan Healthy Mom (MI-MOM) Pregnancy Improvement Web Application Trial
- Shiawasee Health Department, Corunna
- McLaren Flint OB-GYN, Flint
- Munson Gaylord OB-GYN, Gaylord
- ak 5 plis
Ap rekrite
Laj 18 ak plis · Fanm · Mizajou Jul 24, 2026 · NCT07213284A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
- Revival Research Institute, LLC, Southfield
Ap rekriteFaz 3
Laj 55 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT07602582A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
- QUEST Research Institute, Farmington Hills
Ap rekriteFaz 1Volontè an sante akeyi
Laj 45 a 85 · Tout sèks · Mizajou Jun 4, 2026 · NCT06657768Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
- Quest Research Institute, Farmington Hills
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 60 a 90 · Tout sèks · Mizajou Apr 15, 2026 · NCT06584357Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.